+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
P

Actively Recruiting

Researchers are evaluating the combination of calderasib and pembrolizumab as a first-line treatment for adults with locally advanced or metastatic non-small cell lung cancer NSCLC that has a specific KRAS G12C mutation and a PD-L1 tumor proportion score of 50% or higher. The study aims to determine if this combination improves progression-free survival compared to pembrolizumab with placebo. This is a phase 3 randomized, double-blind trial sponsored by Merck Sharp & Dohme LLC. Participants will receive pembrolizumab 200 mg through intravenous infusion on the first day of each 21-day cycle, continuing for up to 35 cycles. In addition, they will take either calderasib or placebo tablets daily until they meet discontinuation criteria. The study includes two groups one receiving calderasib plus pembrolizumab and the other receiving placebo plus pembrolizumab. No new participants will be offered a second course of pembrolizumab. Throughout the study, participants will undergo various assessments including tumor evaluations by central review to measure progression-free survival, overall survival, and response rates. Quality of life and physical functioning will be monitored using standardized questionnaires up to 24 months. Safety will be tracked by recording adverse events and treatment discontinuations for up to approximately 80 months. The total study duration extends up to 7 years, with ongoing monitoring throughout.

Age: 18Years +All GendersPhase 3
246 locations
S

Actively Recruiting

Researchers are evaluating a shorter treatment duration with androgen receptor pathway inhibitors ARPIs, specifically Apalutamide or Enzalutamide, in patients with low-volume hormone-sensitive metastatic prostate cancer. This phase 3 clinical trial aims to determine if stopping ARPI therapy after 12 months, with the option to restart if the cancer progresses, is not worse than continuing ARPI treatment. The goal is to reduce side effects and costs while maintaining effective disease control. Participants will be randomly assigned after completing 12 months of ARPI treatment to one of two groups one group will continue androgen deprivation therapy ADT combined with ARPI, while the other will stop ARPI after 12 months but may restart it if a confirmed rise in prostate-specific antigen PSA occurs. The PSA confirmation sample must be taken at least four weeks after the initial rise. Treatment will be monitored closely according to these protocols. During the study, participants will be followed for up to 6 years, including 5 years after randomization to track clinical progression-free survival. Researchers will regularly assess disease status, treatment effects, and possible side effects. The study includes regular visits and monitoring to evaluate how long patients remain free from disease progression while comparing the two treatment approaches.

Age: 18Years +MALEPhase 3
26 locations
E

Actively Recruiting

Researchers are evaluating the AtMoves Knee System to improve the diagnosis of aseptic loosening in patients who have received a total knee replacement. The main goal is to find out if using this specialized device during a CT scan can reduce the number of failed outcomes, defined by patient-reported knee function scores not showing meaningful improvement at 12 months. The study compares two groups to see if the AtMoves Knee System helps in clinical diagnosis and treatment decisions. Participants are randomly assigned to one of two groups. The intervention group undergoes a CT scan using the AtMoves Knee System, which applies specific forces to detect movement of the knee prosthesis component. Both groups continue with diagnostic and treatment plans determined by their orthopedic surgeons, with the control group not receiving the specialized CT scan. This allows researchers to assess the added value of the AtMoves system in routine clinical care. During the one-year follow-up period, participants complete questionnaires about their knee function. Researchers will track the percentage of failed outcomes, revision surgeries, diagnostic activities, related costs, medical use after diagnosis, societal productivity loss, and participant satisfaction with the AtMoves procedure. The study aims to provide a comprehensive evaluation of this diagnostic tools impact on patient outcomes and healthcare use.

Age: 18Years +All GendersPhase Not Applicable
7 locations
C

Actively Recruiting

Acute urinary retention AUR is a sudden and painful condition where a man cannot urinate, often caused by an enlarged prostate known as benign prostatic hyperplasia BPH. Treatment usually starts with inserting a catheter to empty the bladder and taking medication called alpha-blockers. This study compares two different lengths of catheter use before trying to urinate again, known as the Trial Without Catheter TWOC, to find out if a shorter catheter period is as effective and safe as a longer one. The trial includes 478 men with AUR who all receive a catheter and start or continue alpha-blocker treatment. Participants are randomly assigned to have the catheter removed either after three days or after fourteen days. The study examines if the shorter catheter duration works as well as the longer one in allowing normal urination without needing catheter replacement. It also looks at complications, patient comfort, quality of life, and healthcare costs. During the study, researchers will monitor how many men need re-catheterization after their TWOC, assess patient-reported symptoms and quality of life at multiple time points up to six months, and track complications and healthcare expenses up to 18 months after catheter insertion. The goal is to identify the best timing for catheter removal to reduce discomfort and complications and improve care. Participation lasts through these assessments and follow-ups as scheduled by the research team.

Age: 18Years +MALEPhase Not Applicable
11 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the MiLES intervention aimed at employers to help employees with cancer successfully return to work. This randomized controlled trial will compare the MiLES intervention to usual care, assessing its effectiveness, cost-effectiveness, and impact on quality of life for employees with cancer and their employers. The study includes 140 pairs of employees with cancer and their employers, focusing on improving return-to-work outcomes within a year. The study involves two groups one where employers access the web-based MiLES intervention featuring interactive videos, conversation checklists, tips, and information to better support employees with cancer during sick leave and return to work and a control group receiving usual care without access to MiLES during the study. Employers in the control group will receive access to MiLES after a 12-month waiting period. The MiLES intervention encourages effective communication and support between employers and employees. Participants will complete questionnaires at the start and at 3, 6, and 12 months to assess return to work, quality of life, work-related support, and satisfaction for both employees and employers. The study also evaluates employers confidence in providing support and satisfaction with the return-to-work process. Researchers will monitor outcomes and perform cost-effectiveness analyses from the employers perspective. The total follow-up period for each participant is 12 months.

Age: 18Years - 65YearsAll GendersPhase 2Phase 3
5 locations
I

Actively Recruiting

Breast cancer affects about one in seven women, and determining if cancer has spread to the lymph nodes is vital for treatment planning and predicting outcomes. This trial evaluates a new method using indocyanine green ICG fluorescence imaging to identify the sentinel lymph node during breast cancer surgery. The study aims to introduce ICG into regular hospital care in the Netherlands, comparing it to the current standard method using a radioactive tracer, technetium-labeled 99mTc-nanocolloid, which has logistical challenges and exposes patients to radiation. The trial is conducted in three phases first, using the standard 99mTc method second, a transition phase combining both 99mTc and ICG and third, fully implementing ICG alone. During surgery, ICG is injected after anesthesia and visualized with a special camera to locate lymph nodes, while 99mTc requires preoperative injection and imaging. The study takes place in several hospitals and involves gradually introducing ICG while monitoring and adjusting the process. Participants undergo sentinel lymph node biopsy during planned surgery with no extra hospital visits. After surgery, they complete a short questionnaire about their experience. Researchers collect data on how well ICG is adopted, patient satisfaction, procedure safety, costs, and surgical outcomes. The trial aims to create medical protocols and educational materials to support widespread, sustainable use of ICG in breast cancer care.

Age: 18Years +All GendersPhase Not Applicable
7 locations
L

Actively Recruiting

Researchers are studying women with node-positive breast cancer who receive neoadjuvant systemic therapy NST, which includes chemotherapy with or without immunotherapy. The study aims to understand the safety and quality of life effects of using less invasive methods compared to more invasive axillary staging and treatment after NST. This is important because patients whose lymph nodes show no remaining cancer after NST may not benefit from extensive lymph node removal, but more evidence is needed about the safety and impact of less invasive approaches. This multicenter observational study collects detailed information on patients treated with NST for node-positive breast cancer. It gathers data about the cancer, staging methods before and after NST, and treatment details from medical records. Patients complete questionnaires about their quality of life at diagnosis, and then 1 and 5 years later. The study database is maintained by the Netherlands Cancer Registry and aims to inform future treatment guidelines. Participants provide information through patient-reported outcome measures and undergo regular clinical follow-up to monitor disease-free survival, breast cancer-specific survival, overall survival, and rates of cancer recurrence in the lymph nodes over five years. Quality of life is assessed using several validated tools at baseline and during follow-up. The study results will help balance treatment decisions between less and more invasive options and support shared decision making for women with this breast cancer type.

Age: 18Years +FEMALE
35 locations
O

Actively Recruiting

Researchers are investigating whether chemotherapy can be safely skipped for patients with certain favorable features of low stage triple-negative breast cancer after surgery and radiation. The study aims to see if avoiding chemotherapy improves patients quality of life. Participants decide with their doctors whether to have chemotherapy or not as part of their treatment. Participants receive surgery and radiotherapy based on local or national guidelines. One group will have chemotherapy omitted, while another group will receive chemotherapy in addition to surgery and radiotherapy. The study compares these two approaches to understand treatment outcomes. Participants will be monitored for up to 96 months to track disease recurrence and survival. Quality of life, fear of recurrence, health worries, and cost effectiveness will be assessed up to 2 years after inclusion. Various questionnaires and clinical evaluations will be used to measure these outcomes and ensure participant safety throughout the study.

Age: 18Years +All Genders
28 locations

1-10 of 12

1